Citius Oncology Reports Nationwide Deployment of LYMPHIR's Broadened Commercial Organization and Expanding Market Adoption

About this update from Citius Pharmaceuticals, Inc.

Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today provided an update on the commercial launch of LYMPHIR® (denileukin diftitox-cxdl), highlighting continued progress across market access, commercial execution, and physician adoption.Citius Oncology has expanded its commercial organization to include 21 additional commercial field-based professionals and added eight medical science liaisons dedicated to supporting complex clinical practitioner engagement and patient care. All personnel are expected to be fully onboarded and deployed nationwide by August 2026.The expansion of the commercial and medical teams was facilitated by the Company's May 2026 financing and implemented by EVERSANA, Citius Oncology's exclusive commercialization partner. EVERSANA also provides Citius Oncology with an integrated suite of operations services including medical information, pharmacovigilance, revenue cycle management, program management, data and analytics, channel management, and patient assistance."We are encouraged with the continued progress of the LYMPHIR launch," said Leonard Mazur, Chairman and Chief Executive Officer of Citius Oncology and Citius Pharmaceuticals. "Over the past several months, we have built substantial commercial momentum, expanded physician awareness, and secured near 100% payer coverage, and we continue to see a growing number of treatment accounts initiating orders. We believe these achievements, combined with the full build out of our salesforce and medical affairs teams, and a substantial number of accounts advancing LYMPHIR through their formulary review process, position LYMPHIR for meaningful growth during the second half of 2026.""We continue to receive encouraging feedback from physicians regarding LYMPHIR's differentiated mechanism of action and clinical profile," added Mr. Mazur. "With all key commercial and medical personnel now in place and adoption trends continuing to build, we believe we are entering an important inflection point for the product."As part of its commercialization strategy, Citius Oncology has also deployed ...

View stock analysis, news, and events for Citius Pharmaceuticals, Inc.